Health & Fitness
Health and Fitness
Health and Fitness 
Wed, March 16, 2011
Tue, March 15, 2011
InSite Vision Announces Annual Shareholder Meeting to be Held on June 1, 2011
ALAMEDA, Calif.--([ BUSINESS WIRE ])--InSite Vision Incorporated (OTCBB: INSV), a company developing ophthalmic products for unmet eye care needs, today announced that the companya™s Annual Meeting of Stockholders will be held at 10:00 a.m. Pacific Time on Wednesday, June 1, 2011, for shareholders of record on April 11, 2011. The Annual Meeting will be held at the companya™s headquarters at 965 Atlantic Avenue, Alameda, California. InSite Vision plans to mail the definitive proxy statement for the Annual Meeting, as well as its annual report, in late-April.
About InSite Vision
InSite Vision is committed to advancing new and superior ophthalmologic products for unmet eye care needs. The companya™s product portfolio utilizes InSite Visiona™s proven DuraSite® bioadhesive polymer core technology, an innovative platform that extends the duration of drug retention on the surface of the eye, thereby reducing frequency of treatment and improving the efficacy of topically delivered drugs. The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite® (azithromycin ophthalmic solution) 1%, marketed in the U.S. by Inspire Pharmaceuticals, and Besivancea" (besifloxacin ophthalmic suspension) 0.6%, marketed by Bausch & Lomb and their partner Pfizer Inc. InSite Visiona™s clinical-stage ophthalmic product pipeline includes AzaSite Plusa" (ISV-502) and DexaSitea" (ISV-305) for the treatment of eye infections, ISV-303 for pain and swelling associated with ocular surgery, and ISV-101 for the treatment of dry eye disease. For further information on InSite Vision, please visit [ www.insitevision.com ].
AzaSite® and DuraSite® are registered trademarks of InSite Vision Incorporated.
BESIVANCEa" is a trademark of Bausch & Lomb Incorporated.